Seroprevalence of Hepatitis B and C Genotypes Among Young Apparently Healthy Females of Karachi-Pakistan by Hakim, ST et al.
www.ljm.org.ly    Original Article  
Libyan J Med, AOP: 071123
Seroprevalence of Hepatitis B and C Genotypes Among Young 
Apparently Healthy Females of Karachi-Pakistan 
 
 Hakim  ST
1, 2, 3, Kazmi SU
2, Bagasra O
3 
 
 
1 Department of Microbiology, Jinnah University for Women, Karachi
 2 I.I.D.R. Lab, University of Karachi, Karachi, Pakistan 
3 South Carolina Center for Biotechnology, Claflin University, South Carolina, USA 
 
Abstract 
Introduction: Although the prevalence of hepatitis virus infections in Pakistan is still unknown, limited data indicate that the 
exposure rate to HBV is 35-38% with 4% being carriers and 32% having anti-HBV surface antibodies through natural 
conversion [1,2,3]. Studies in Pakistan have shown that the prevalence rate of HCV is 4.8-14% for, and that it is continuously 
increasing. Hence there is an urgent need to create awareness about the prevalence of both hepatitis B and C, and to develop 
preventive measures aimed at minimizing the prevalence of these diseases in the country. Study Design: Prospective, 
descriptive study. The study took place from March 2002 till October 2006 at two university campuses in Karachi. Materials
and methods: A total of 4000 healthy female students were screened for HBs Ag, anti-HBs antibodies and anti-HCV 
antibodies by rapid immunochromatography, ELISA and PCR. Results: A total of 3820 volunteers (95.5%) were negative by 
all three methods, 181 (4.5%) tested positive for HB surface antigen and 20 (0.5%) were positive for anti HB surface 
antibodies; 208 volunteers (5.2%) were positive for HCV. Double infection with HBV and HCV was found in only one patient 
(0.025%). Out of 180 HBs antigen positive samples 151 (83.89%) were genotype D, 28 (15.56%) showed mixed infection 
with genotypes B and D, and one patient (0.56%) showed mixed infection with genotypes C and D. Out of 208 samples 
positive for HCV antibodies, 107 (51.44%) were genotype 3a, 50 (24.04%) were mix of genotype 3a and 3b, 33 (15.87%) 
were genotype 3b, 10 (4.81%) were genotype 1b while, 8 (3.84%) samples could not be typed. Conclusion: Although the 
presence of these pathogenic viruses was not very high in our young healthy female population, it is still a matter of concern 
to control the unregulated spread of these deadly infections by promoting increased awareness and regular immunization 
programs in the community. Local manufacturing of vaccines and related products may reduce these infections. 
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Introduction 
In Pakistan, it is estimated that at least nine million 
people harbor Hepatitis B virus, and over fourteen million 
are chronically infected with Hepatitis C virus 
[1,2,11,19,21-27]. The exact prevalence rate of Hepatitis 
virus infections in Pakistan is unknown, and most studies 
have been done in different small groups, e.g. blood 
recipients, paid blood donors, patients suffering from liver 
disorders, hemodialysis patients, health care workers and 
voluntary blood donors [24,25,28,29]. Earlier studies done 
in Pakistan have shown a prevalence rate of 4-10% for 
HBV and 4.8-14% for HCV [30,31]. Recent data indicate 
the prevalence of HBV might be declining, probably 
because of increased awareness and wide acceptance of 
health care measures, including mass vaccination program 
undertaken by the government [4,5,6]. On the other 
hand, the burden of HCV-related chronic liver disease 
(CLD) in Pakistan has increased [7,8,12-18]. 
 
Earlier studies showed that of all patients presenting 
with CLD, 16.6% were anti-HCV positive [32]. 
Furthermore, recent data show that 60-70% of patients 
with CLD tend to be positive for anti-HCV [31, 33,34,35]. 
It has been demonstrated that nearly 50% of patients 
with hepatocellular carcinoma (HCC) in Pakistan are anti-
HCV positive [36]. The main purpose of this study was to 
investigate the prevalence of HBV and HCV in young, 
apparently healthy women of childbearing age in a large 
city. Women are expected to be the major victims of 
infections such as HBV, HCV and HIV because of greater 
exposure to syringes, blood and blood products, especially 
during pregnancy, delivery and ear piercing. Another 
purpose was to make these women aware of those 
infections, which can be prevented easily by practicing 
simple precautionary measures such as regular health 
checkups and vaccination [9,10,20,53]. These young 
women can further educate their families and thereby 
indirectly play a role in reducing the burden of these kinds 
of diseases. 
 
Materials and methods 
Ethical issues 
Informed signed consent was collected from all 
volunteers who participated in the study, after the 
purpose, nature and risks of the participation were fully 
explained to them verbally and in writing. The individual 
laboratory results were kept confidential and given to the 
participants at the completion of the project. Also, they 
were provided with information on limiting the spread of 
these infections and referred to the nearest government 
medical facility for guidance. 
  
Subjects
A total of 4000 healthy female students from two 
universities in Karachi, aged 18-30 years, participated in 
this study. 
 
Study Plan and Design 
To obtain enough volunteers, six screening camps were 
organized at the Department of Microbiology, University of 
Karachi, and the Department of Microbiology, Jinnah 
University for women, Karachi, during March 2002 and 
October 2006.  Every camp followed an awareness lecture 
on “Hepatitis infections, their consequences, and 
preventive measures”, to create awareness about the 
importance of regular health checkups and hepatitis 
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screening. After submitting their signed consents, 
volunteers were subjected to health checkups by a 
medical doctor. 
 
Inclusion Criteria 
Age 18 to 30 years; weight: >45 kg; body temperature 
96 to 98°F; hemoglobin >10 g/dl, blood pressure: systolic 
100-180 mm, diastolic: 60-100 mm; pulse rate >65/min. 
Clinical history of volunteers was noted, especially 
jaundice, blood transfusion, exposure to syringes, surgical 
and dental procedures. 
 
Exclusion Criteria 
Apparently unhealthy or malnourished individuals were 
excluded. 
 
Pre study screening 
From every volunteer 15 ml of blood was taken. Serum 
was separated by centrifugation and stored at –20ºC. 
1. Hematologic screening (hemoglobin, red cell count, 
total and differential white cell count, hematocrit, platelet 
count, mean cell volume, mean cell hemoglobin 
concentration) was done using a Sysmex-KX-21 
hematology analyzer (S. Ejazuddin & Company, Pakistan). 
2. Biochemical screening (total bilirubin, direct bilirubin, 
ALT, AST and alkaline phosphatase) was done using a 
Microlab 200 analyzer (Merck, Germany). 
3. HBV and HCV screening: On the spot screening for 
HBs Ag, anti HBs antibodies and HCV antibodies was done 
by using rapid immunochromatography kits (ICT, Australia 
and Abbott, USA). 
 
Confirmatory tests for HBs Ag and HCV antibodies were 
done by using ELISA (IMX, Abbott, USA). 
1. HBV DNA and HCV RNA were extracted from 200 μl 
of serum using Purelink viral RNA/DNA Mini Kit 
(Invitrogen, USA; for procedure refer to the 
manufacturer’s instructions). 
2. All positive cases were further confirmed by PCR 
using puReTaq Ready-To-Go PCR Beads (Amersham, UK/ 
USA; for procedure refer to the manufacturer’s 
instructions). 
 
Results
Before screening, all volunteers were subjected to 
routine physical checkups for exclusion criteria. A total of 
4000 healthy women were screened by 
immunochromatography for the presence of HBsAg, anti 
HBs antibodies and HCV antibodies. Positive results were 
confirmed by ELISA. We found 3820 (95.5%) subjects 
negative by both immunochromatography and ELISA, 181 
(4.5%) tested positive for HB surface antigen, 20 (0.5%) 
were positive for anti-HB surface antibodies, and 208 
(5.2%) were positive for anti-HCV antibodies. Only two 
volunteers (0.05%) were infected with both HBV and HCV 
(Table1). 
 
WBC count, RBC count, hematocrit and platelet count in 
the 181 HbsAg-positive individuals were within normal 
range, while mean Hb was 9.8±1.6 g/dl. Direct bilirubin, 
indirect bilirubin, ALT, AST and alkaline phosphatase were 
within normal range in all tested individuals, except for the 
raised ALT and AST levels in 10 participants with a 
previous history of jaundice who were positive HBsAg. Of 
208 participants who scored positive for HCV antibodies, 
13 showed elevated amino transferase activity (AST) and 
raised ALT levels (Table 2). 
 
All samples that were positive for HBs antigen or HCV 
antibodies were later on confirmed by PCR. Out of 181 
HBs antigen positive samples, 151 (83.42%) were 
genotype D, 28 (15.46%) showed mixed infection with 
genotypes B and D, while one (0.025%) showed mixed 
infection of genotypes C and D (Table 3). Out of 208 
samples positive for HCV antibodies, 107 (51.44%) were 
genotype 3a, 50 (24.03%) were a mix of genotype 3a and 
3b, 33 (15.86%) were genotype 3b, 10 (4.80%) were 
genotype 1b while, and 8 (3.84%) samples could not be 
typed (Table 4). 
 
Table 1  Prevalence of HbsAg, and ANTI-HBs and anti-HCV 
antibodies in 4000 volunteers. Mean age was 21.5 years (SEM 
+3.7 years). The number of volunteers in each column is followed 
by the percentage parentheses. 
HbsAg-
positive
Anti-HBs 
antibodies 
positive 
Anti-HCV 
antibodies 
positive 
Anti-HBc  
IgM 
antibodies 
Negative
Mixed 
infection: 
HBV & HCV
181 
 (4.5%)
20  
(0.5%) 
208 
(5.2%) 
00 
(0.0%) 
3819 
 (95.5%)
01 
(0.025%)
Table 2  Biochemical/ Hematological & Serological profiles of HBV 
Genotypes. Values are given as mean +  SEM 
  HbsAg 
Positive
(n=181)
HBcAg
Positive 
(n=7)
HBcAg
Negative 
  (n=7) 
Sex  (F)  181 07 173 
Age (yrs.) 
  20.5+ 3.2    21.0+3.1    20.9+3.0 
Total serum 
bilirubin (mg/dl)    0.91+0.8    1.0+0.3    0.85+0.2 
ALT (U/L) 
  50+ 3    67+ 9    52+2 
Alkaline 
phosphatase (U/L)   210+35    209+ 15    196+20 
Serum Albumin 
(g/dl)    4.1+0.8    5.0+0.5    4.0+0.5 
Platelet count 
(10
9/L)    407+60    425+80    410+30 
Genotype D 
181   7 173 
Coinfection with 
genotype B   28   2   26 
Coinfection with 
genotype C  1   0   1 
Table 3  Genotypic Distribution of HBV With respects To Single & 
Mixed Infection; the number of volunteers in each column is 
followed by the percentage within parentheses. 
Genotype D 
B & D 
mixed 
infection 
C & D 
mixed 
infection 
Total 
Number 
151 
( 83.88%)
 28 
( 15.56%) 
1 
(0.56%) 
180 
(100%) 
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Table 4  Genotypic Distribution of HCV with Respect To Single & 
Mixed Infection; The number of volunteers in each column is 
followed by the percentage within parentheses. 
Genotype 3a 
3a & 3b 
mixed 
infection 
3b 1b 
Could 
not be 
typed 
Number 
107 
(51.44%) 
 50 
(24.04%) 
33 
(15.87%) 
10 
(4.81%) 
8 
(3.84%)
 
Discussion
Confirmation of a diagnosis of hepatitis B and 
assessment of prognosis rely on examination of liver 
biopsy. Most people who are chronic inactive carriers (no 
symptoms, HbsAg-positive, normal serum 
aminotransferase activity) generally have little or no 
inflammation on biopsy. An important feature in such 
patients is the presence of "ground glass cells" in liver 
biopsy, i.e. liver cells producing large amounts of HbsAg. 
Individuals with chronic hepatitis B have various degrees 
of liver inflammation, and some have fibrosis or cirrhosis. 
Substantial inflammation and the presence of fibrosis or 
cirrhosis correlate with a worse prognosis. A major 
problem estimating prognosis of patients with chronic 
hepatitis C is that it is difficult to predict who will have a 
relatively benign course and who will go on to develop 
cirrhosis or cancer. One clear factor for progression to 
cirrhosis is concurrent alcohol abuse. Viral genotype may 
also play a role. 
 
There is a wide variation in the prevalence of anti-HCV 
antibodies and HBsAg worldwide. The global prevalence of 
HCV is 3% [37]. The prevalence of HCV is high in Africa, 
especially in some Egyptian cities where more than 15% 
of the population is infected [38]. The carrier rate of HBs 
Ag varies from 0.1% to 0.2% in Britain and USA, more 
than 3% in Greece and southern Italy, and up to 15% in 
Africa and the Far East [39]. Pakistan is highly endemic 
with hepatitis B and hepatitis C [40]. Studies are too 
limited to give a clear picture of the prevalence of hepatitis 
B and hepatitis C at the national level, especially among 
apparently healthy individuals. Most previous studies 
targeted different small groups of individuals with some 
clinical indications, so they do not accurately reflect the 
overall prevalence in Pakistan. 
 
For example, the prevalence of HBsAg has been 
variously reported as 9.97%, 10%, 3.1%, 0.99%, 1.11%, 
4%, 3%, 3.2%, 3%, 4.3% and 6.5%, respectively, in 
different groups of individuals  [28,39,41-49]. On the 
other hand, seroprevalence of HCV antibodies has been 
variously reported as 4%, 16.3%, 4.8%, 2.2%, 3.3%, 
16% and 11.3%, respectively [46,47,49,50-53] (Table 5). 
 
Available data indicates that HBV has been classified 
into eight genotypes (A -H), according to the criterion of 
8% differences in the complete nucleotide sequence of the 
viral genome [54,55,56,57]. HCV is divided into six 
genotypes with numerous subtypes. These genotypes can 
differ by up to 30% from each other in nucleotide 
sequence. These genotypes have different geographic 
distributions. In addition to the epidemiological 
importance, these genotypes may influence the disease 
pattern and response to treatment [58], and so it is 
important to identify the virus genotype. 
 
In our study we selected subjects who were apparently 
healthy and fit our basic inclusion criteria based on age, 
weight, body temperature, pulse rate, blood pressure and 
previous clinical history. For that reason, almost all 
participants had normal hematological biochemical values 
(Table 2). Noteworthy, however, is that 10 HBsAg-positive 
volunteers had elevated levels of AST (>31 U/L) and ALT 
(>36 U/L), and 13 volunteers who were positive for HCV 
antibodies had elevated alkaline phosphatase level (>270 
U/L). 
 
The prevalence rate of HBsAg we observed among 
apparently healthy women (4.5%) is close to previously 
reported rates [43,45,47-66]. Prevalence of HCV 
antibodies (5.2%) is also similar to rates previously 
reported in healthy individuals [39,46,47]. Genotyping 
results showed that all HBV-positive individuals had 
genotype D, either alone or in a mixed infection (Table 3). 
In HCV-positive individuals, genotype 3a was the most 
common (51.44%), followed by 3b (15.87%) (Table 4). 
 
Over 350 reports, papers and presentations estimate 
the combined prevalence of hepatitis B and C in various 
parts of Pakistan at 8-10%. A  substantial decline in 
hepatitis B has been observed due to mass scale 
immunization program started with government support 
against HBV infection. However, the prevalence of 
hepatitis C has risen due to improper screening of blood, 
unavailability of vaccine and other modes of transmission. 
Due to the high cost of treatment of hepatitis B and C 
virus infection and the unavailability of a vaccine against 
HCV, the main focus should be on preventive aspects. 
Here comes the importance of identifying the genotype of 
the virus infecting a person, which is not a common 
practice in Pakistan. Mostly treatment is given without 
knowing the genotype, which may result in no response or 
emergence of mutant strains of the virus. 
 
In Pakistan there is an urgent need to raise public 
awareness, which can be accomplished through programs 
in schools, colleges, and universities, and through 
information media about the value of immunization and 
preventive measures. Women are considered to play the 
main role in the families. Infected women can spread 
infection among their family members, especially 
infections such as HBV and HCV. Their health and 
education in health related issues could have a broad 
impact on the overall health status of the country. Besides 
awareness programs and improved treatment strategies, 
we also need to evaluate the available HBV vaccines in the 
market for their proper storage, their efficacy, side effects 
and immunogenicity. 
 
Conclusion
Genotype D was the predominant type of HBV (100%), 
and types 3a (51.44%) and 3b (15.86%) were the 
predominant types of HCV among the apparently healthy 
women participating in this study. Prevalence of HBV and 
HCV was 4.5% and 5.2%, respectively. Attempts should 
be made to reduce the incidence of HCV and HBV and 
their unregulated spread. This can be done by increasing 
public awareness of simple preventive measures. We also 
need to have similar studies at a national level to 
determine the overall prevalence and incidence of 
hepatitis infections in Pakistan. 
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